Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO · Real-Time Price · USD
484.79
+7.38 (1.55%)
At close: Aug 13, 2025, 4:00 PM
485.00
+0.21 (0.04%)
Pre-market: Aug 14, 2025, 4:42 AM EDT
Thermo Fisher Revenue
Thermo Fisher had revenue of $10.86B in the quarter ending June 28, 2025, with 2.98% growth. This brings the company's revenue in the last twelve months to $43.21B, up 2.05% year-over-year. In the year 2024, Thermo Fisher had annual revenue of $42.88B with 0.05% growth.
Revenue (ttm)
$43.21B
Revenue Growth
+2.05%
P/S Ratio
4.26
Revenue / Employee
$345,696
Employees
125,000
Market Cap
183.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 42.88B | 22.00M | 0.05% |
Dec 31, 2023 | 42.86B | -2.06B | -4.58% |
Dec 31, 2022 | 44.92B | 5.70B | 14.55% |
Dec 31, 2021 | 39.21B | 6.99B | 21.71% |
Dec 31, 2020 | 32.22B | 6.68B | 26.14% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TMO News
- 2 days ago - Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside - Seeking Alpha
- 2 days ago - Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment - Business Wire
- 5 days ago - Thermo Fisher: The Rerating Is Just Getting Started - Buy - Seeking Alpha
- 6 days ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 6 days ago - Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts - Seeking Alpha
- 7 days ago - Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets - Seeking Alpha
- 16 days ago - Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025 - Business Wire
- 20 days ago - Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference - Business Wire